A Phase I trial of talazoparib in patients with advanced hematologic malignancies

AIM: The objective of this study was to establish the maximum tolerated dose (MTD), safety, pharmacokinetics, and anti-leukemic activity of talazoparib. PATIENTS & METHODS: This Phase I, two-cohort, dose-escalation trial evaluated talazoparib monotherapy in advanced hematologic malignancies (coh...

Täydet tiedot

Bibliografiset tiedot
Päätekijät: Gopal, Ajay K, Popat, Rakesh, Mattison, Ryan J, Menne, Tobias, Bloor, Adrian, Gaymes, Terry, Khwaja, Asim, Juckett, Mark, Chen, Ying, Cotter, Matthew J, Mufti, Ghulam J
Aineistotyyppi: Online Artikkeli Teksti
Kieli:English
Julkaistu: Future Medicine Ltd 2021
Aiheet:
Short Communication
Linkit:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8609999/
https://www.ncbi.nlm.nih.gov/pubmed/34840720
http://dx.doi.org/10.2217/ijh-2021-0004

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8609999/
https://www.ncbi.nlm.nih.gov/pubmed/34840720
http://dx.doi.org/10.2217/ijh-2021-0004

Samankaltaisia teoksia